AQR Capital Management LLC Sells 8,205 Shares of Enovis Co. (NYSE:ENOV)

AQR Capital Management LLC trimmed its holdings in shares of Enovis Co. (NYSE:ENOV) by 37.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,707 shares of the company’s stock after selling 8,205 shares during the period. AQR Capital Management LLC’s holdings in Enovis were worth $615,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ENOV. GAMMA Investing LLC increased its stake in Enovis by 19.9% during the first quarter. GAMMA Investing LLC now owns 1,085 shares of the company’s stock worth $68,000 after purchasing an additional 180 shares during the period. State of Michigan Retirement System boosted its position in shares of Enovis by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 12,202 shares of the company’s stock worth $762,000 after purchasing an additional 300 shares in the last quarter. Swiss National Bank boosted its position in shares of Enovis by 0.3% in the 1st quarter. Swiss National Bank now owns 97,000 shares of the company’s stock worth $6,058,000 after buying an additional 300 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in Enovis by 28.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock valued at $76,000 after purchasing an additional 371 shares during the last quarter. Finally, Pitcairn Co. increased its stake in shares of Enovis by 6.8% during the 1st quarter. Pitcairn Co. now owns 6,036 shares of the company’s stock valued at $377,000 after acquiring an additional 386 shares during the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Up 3.9 %

NYSE:ENOV opened at $40.22 on Monday. Enovis Co. has a 1 year low of $38.27 and a 1 year high of $65.03. The company has a current ratio of 2.26, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. The stock has a market cap of $2.25 billion, a price-to-earnings ratio of -24.23 and a beta of 1.91. The stock has a 50-day moving average price of $43.10 and a two-hundred day moving average price of $47.82.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.03. The company had revenue of $525.20 million during the quarter, compared to analysts’ expectations of $525.99 million. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. Enovis’s revenue for the quarter was up 22.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 earnings per share. As a group, equities analysts expect that Enovis Co. will post 2.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Needham & Company LLC reduced their price objective on Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Evercore ISI cut their price target on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. JMP Securities assumed coverage on Enovis in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price target on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and an average price target of $67.89.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.